AlmataBio
AlmataBio is a private, Atlanta-based biotechnology company that, per its firmographic profile, develops an antibody targeting hidradenitis suppurativa and other inflammatory diseases; no operational, pipeline, or financial details are publicly disclosed, and its web domain is currently parked.
- Company typePrivate
- Founded-
- HeadquartersAtlanta, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
AlmataBio firmographics
Firmographics- Name
- AlmataBio
- Website
- https://almatabio.com
- Company type
- Private
- Short description
- AlmataBio is a private, Atlanta-based biotechnology company that, per its firmographic profile, develops an antibody targeting hidradenitis suppurativa and other inflammatory diseases; no operational, pipeline, or financial details are publicly disclosed, and its web domain is currently parked.
- Ownership category
- akta.pro rank
AlmataBio industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
Keywords
Where AlmataBio is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Markets served
AlmataBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
AlmataBio product offering
Product offeringCore offering
AlmataBio specializes in the development of antibody-based therapeutics aimed at preventing hidradenitis suppurativa and other inflammatory diseases. The company is described as a biopharmaceutical entity focused on antibody discovery and development targeting inflammatory conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Anti-inflammatory antibody therapeutic (hidradenitis suppurativa)
Companies that use AlmataBio
Customer profileIdeal customer profiles1 record
AlmataBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AlmataBio competitors and assessment
Company assessmentEmerging players
- ChemoCentryx: Small-cap inflammation biotech with complement pathway antibody programs (acquired by Amgen). Comparable as an emerging inflammation-focused biologic developer with a similar scale profile to a hypothetical AlmataBio.
- Arcturus Therapeutics: Smaller-stage biotech developing nucleic acid and protein-based therapies for inflammatory and rare diseases. Comparable in scale and stage to AlmataBio as an emerging inflammation-modality developer.
Broad incumbents
- Sanofi / Regeneron: Dupilumab (Dupixent) is in development for HS and other inflammatory skin diseases. Comparable as a large inflammation antibody developer that competes for the same patient population and prescribers AlmataBio would target.
- UCB: Global biopharma with bimekizumab (Bimzelx) approved for HS. Comparable as a large immunology player with a recent HS antibody approval, defining the competitive benchmark for any new HS antibody entrant.
- Novartis: Pharma major with Cosentyx (secukinumab) approved for HS. Comparable as a broad incumbent whose IL-17 antibody franchise sets efficacy expectations for HS antibody programs.
- AbbVie: Major immunology incumbent with approved HS therapies (Humira, Skyrizi/Risankizumab). Indirectly comparable as the leading commercial competitor in the hidradenitis suppurativa biologic space that AlmataBio would need to displace or differentiate from.
- Janssen (Johnson & Johnson Innovative Medicine): Develops Tremfya (guselkumab) and other IL-23 antibodies relevant to HS and inflammatory disease. Comparable as a broad incumbent in inflammatory dermatology antibodies.
Direct peers
- InflaRx: Biotech focused on anti-inflammatory therapeutics with an HS clinical program (vilobelimab). Comparable as a small-cap inflammation/HS-focused antibody developer pursuing the same indication as AlmataBio.
- MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing sonelokimab, an IL-17A/F nanobody being advanced in hidradenitis suppurativa. Directly comparable to AlmataBio in indication (HS) and modality (antibody-derived biologic for inflammatory disease).
Market position
Customer concentration
AlmataBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AlmataBio leadership team
Management profileNumber of profiles
AlmataBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AlmataBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AlmataBio
What does AlmataBio do?
AlmataBio specializes in the development of antibody-based therapeutics aimed at preventing hidradenitis suppurativa and other inflammatory diseases. The company is described as a biopharmaceutical entity focused on antibody discovery and development targeting inflammatory conditions.
When was AlmataBio founded?
AlmataBio was founded in -1.
Where is AlmataBio based?
AlmataBio is headquartered in Atlanta, United States, in the North America region.
Who are AlmataBio's main competitors?
Emerging players on record are ChemoCentryx and Arcturus Therapeutics. Broad incumbents are Sanofi / Regeneron, UCB, Novartis, AbbVie and Janssen (Johnson & Johnson Innovative Medicine). Direct peers are InflaRx and MoonLake Immunotherapeutics.
Does AlmataBio have an API?
No public API is recorded for AlmataBio.
What industry is AlmataBio in?
AlmataBio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.